Pharmacogenetics of smoking cessation in general practice: results from the patch II and patch in practice trials.

ABSTRACT:

Introduction

Cigarette smoking remains the leading cause of preventable death worldwide. However, the efficacy of available first-line therapies remains low, particularly in primary care practice where most smokers seek and receive treatment. These observations reinforce the notion that 'one size fits all' smoking cessation therapies may not be optimal. Therefore, a translational research effort was launched by the Imperial Cancer Research Fund (later Cancer Research UK) General Practice Research Group, who led a decade-long research enterprise that examined the influence of pharmacological hypothesis-driven research into genetic influences on drug response for smoking cessation with transdermal nicotine replacement therapy in general practice.

Methods

New and previously pub

SUBMITTER: David SP 

PROVIDER: S-EPMC3107615 | biostudies-literature | 2011 Mar

REPOSITORIES: biostudies-literature